On Dec. 1, 2020, VBI Vaccines announced the submission of a Biologics License Application (BLA) to the FDA seeking approval of the Companyﾒs 3-antigen prophylactic hepatitis B vaccine candidate, for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

This vaccine is a 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and was approved for use and commercially-available in Israel, under the name Sci-B-Vacﾮ.